Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-Surg
NCT04386070Phase 3Suspended
- Sponsor
- University of Birmingham
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of RESP301 in Pulmonary complication and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Birmingham. Primary endpoint: Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death up to 30 days. Started May 2022; status: suspended.
02
Drugs
RESP301
03
Conditions
Pulmonary complicationcoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04386070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386070.